Loading stock data…
$1.02+0.02 (+2.31%)
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. in the Healthcare sector is trading at $1.02 with a market capitalization of $4M. Wall Street consensus targets $14.00 (3 analysts), implying a +1272.5% move over the next 12 months. The stock is currently near its 52-week low of $0.82, remaining 76.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.34M↓ | -$2.51M↑ | -$3.07M↓ | -$2.73M↑ | -$3.73M |
| Net Income | -$3.32M↓ | -$2.50M↑ | -$3.04M↓ | -$2.69M↑ | -$3.67M |
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 ...